News
The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
LLY Stock Price
$989.87
LLY 5-Year Gains
432.2%
ABBV 1-Year TSR
14.17%
Key driverAsset reallocation and international expansion offset regulatory scrutiny concerns
Daily briefHealthcare· Money365.Market AI ·

Pfizer Divests PROTAC Therapy; Lilly Expands Globally

Big Pharma reshuffles assets as regulatory approvals expand geographic reach and oral obesity therapies advance

Big Pharma & Biotech

Neutral
PFELLYABBV
Pfizer ($PFE) has transferred global development and commercialization rights for VEPPANU (vepdegestrant), the first FDA-approved PROTAC therapy for certain advanced breast cancer patients, to Rigel Pharmaceuticals in a licensing deal that allows $PFE and Arvinas to retain economic interests. Separately, Pfizer secured expanded European Commission approval for Hympavzi hemophilia drug covering patients ages 12 and older with hemophilia A or B with inhibitors, based on Phase 3 data demonstrating superior bleed reduction to on-demand therapy.
Eli Lilly ($LLY) released late-phase clinical data showing patients with obesity maintained significant long-term weight loss after switching from injectable to oral therapies, highlighting Foundayo and Zepbound as durable weight management options with a consistent safety profile for its new oral GLP-1 therapy. The company, trading at $989.87 with 5-year share price gains of 432.2%, launched its Alzheimer's drug Lormalzi (Donanemab) in India, expanding geographic reach for its neuroscience portfolio.
AbbVie ($ABBV) presented fresh real-world and long-term data for key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting, while JNJ-4804 produced positive data in highly refractory inflammatory bowel disease patients. Despite the clinical progress, $ABBV shares have declined 9.35% year-to-date, though the 1-year total shareholder return stands at 14.17%.

Vaccine & Infectious Disease Programs

Bullish

MRNA Share Change

10.2%+10.2%
MRNA
Moderna ($MRNA) shares jumped 10.2% following the publication of positive Phase 3 clinical trial results for its seasonal flu vaccine candidate, mRNA-1010, and announcement of positive Phase 1 data for its hantavirus vaccine. The dual data releases highlight $MRNA's continued expansion beyond COVID-19 into broader infectious disease prevention, though analysts note the company remains money-losing and faces regulatory risks despite its potential as a pandemic hedge.

MedTech & Devices

Neutral

nVision Series B

$55 million

nVision Total Raised

$120 million
ABTJNJISRG
Abbott Laboratories ($ABT) anchored a $55 million Series B financing round for nVision, bringing the medical device company's total capital raised to $120 million. The investment signals continued interest in diagnostic and medical device innovation from major healthcare companies.
Johnson & Johnson ($JNJ) launched the Shockwave C2 Aero Coronary IVL Catheter for calcified coronary artery disease, expanding its intravascular lithotripsy portfolio. The company also reported key clinical results for TREMFYA in perianal fistulizing Crohn's disease, representing the first major trial in this setting in roughly 20 years, while advancing its OTTAVA surgical robotics platform.
Intuitive Surgical ($ISRG) faces FDA Class I recalls on certain da Vinci stapler components and visible institutional selling, reflecting elevated concern around product safety and regulatory scrutiny despite earlier strong quarterly results. The developments highlight how regulatory risk and large investor behavior can quickly influence perceptions of an otherwise growing, cash-generative business model.

Analyst Updates & Price Targets

Neutral

UNH PT (JPM)

$420

ABBV PT (Evercore)

$236

MRK PT (Citi)

$125

MRK Dividend Yield

3.06%
UNHABBVMRK
UnitedHealth Group ($UNH) received a price target increase from JPMorgan to $420 from $389 in late April, reiterating an Overweight rating on the managed care leader.
AbbVie ($ABBV) received a price target lift from Evercore ISI to $236 from $232 while maintaining an Outperform rating on May 4.
Merck ($MRK) was reinstated by Citi with a Neutral rating and $125 price target on May 7, with the company offering an annual dividend yield of 3.06%.

Looking Ahead

Neutral
LLYPFEABBVMRNAISRG
Healthcare investors face a complex backdrop balancing clinical progress against regulatory scrutiny and asset reallocation strategies among major pharmaceutical companies. The successful transition of obesity patients to oral therapies and continued expansion of immunology franchises suggest durable growth opportunities, while device makers navigate safety concerns and recall risks. Biotech names leveraging platform technologies for infectious disease vaccines remain volatile but offer asymmetric upside in outbreak scenarios, while managed care stocks continue attracting institutional support despite broader sector headwinds.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy